The notion that volunteers could be harmed in a clinical trial is every drug developer’s worst nightmare. Earlier this year, the drug company, Bial, investigated inhibitors of the enzyme fatty acid amide hydrolase (FAAH) in clinical trials as a treatment for pain. Tragically, one person in the volunteer group died, and six patients were hospitalized. […]Read More
Author: Neil Benson
Neil has 20 years’ experience of working in modeling and simulation in the pharmaceutical industry at SmithKline Beecham and Pfizer. During this time, he held a number of senior leadership positions, most recently as Head of Systems Pharmacology at Pfizer, Sandwich. He was awarded the Pfizer Upjohn award for innovation in developing dose prediction methodology.
He has extensive experience of using modeling and simulation to address questions of critical importance in drug discovery including; clinical dose prediction, optimal target identification and biomarker selection and has authored ~ 30 papers and patents. From 2011-2015 he was Founder and Director at Xenologiq Ltd, a consultancy company focused on the productive application of PKPD and Systems Pharmacology in drug discovery. In 2015, Xenologiq Ltd became part of the Certara group of companies, where he is now Head of QSP Operations.
Educated at the University of East Anglia (UK) and the University of Lund (Sweden), Neil has a First Class Honors degree and a PhD in enzymology.